Following a share price correction, Maybank Kim Eng Research analyst Lai Gene Lih has upgraded Raffles Medical Group to “buy” on improved risk-reward. Lai’s target price on the medical services provider, however, remains unchanged at 99 cents.

“RMG’s key sustainability factor is ensuring patient safety and regulatory compliance. Raffles Hospital Singapore (RHS) is also JCI accredited since 2008, underscoring its commitment to patient safety and quality healthcare. RMG also places strong emphasis on employee welfare and diversity. Key risk is slower than expected recovery of foreign patient volumes,” writes Lai in a report dated Sept 30.

See: Raffles Medical might have gone regional but Covid war brings it back to the homefront

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook